This content is from:Premium An Under-the-Radar Hedge Fund Reaps Big IPO Rewards Bihua Chen’s Cormorant Asset Management is scoring big gains from development stage biopharma companies. ByStephen Taub December 17, 2020
This content is from:Premium Perceptive Gets a Big Boost From Pfizer’s Array Deal The healthcare and biotech specialist enjoyed hefty gains in many of its top holdings on Monday. ByStephen Taub June 18, 2019
亚博篮球怎么下串 Fireside Chat: $15.7 Billion. Interested? Sponsored byBattea Class Action Services July 15, 2020
This content is from:Premium Where EcoR1 Stands to Profit From Healthy Deal Making Biopharma companies backed by EcoR1 Capital have filed plans this week for public offerings. ByStephen Taub November 13, 2020
This content is from:Premium Nuvation Bio Flounders After EcoR1 SPAC Merger In just five days the shares of the biopharma company that merged with Oleg Nodelman’s blank check company fell by more than one-third. ByStephen Taub March 31, 2021
This content is from:Premium These Hedge-Fund-Backed Companies Are Going Public — And Not Through SPACs Hedge funds including Viking, Citadel, and Point72 are gearing up for five biopharma company IPOs. ByStephen Taub March 09, 2021
